Veloxis Pharmaceuticals announced that LCP-Tacro successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002.
The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf as the comparator, met its primary efficacy and primary safety endpoints.
The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
"The results observed in this clinical trial suggest that new kidney transplant patients can begin with a regimen of once-daily LCP-Tacro™ rather than twice-daily as required with current tacrolimus products, without compromising efficacy and tolerability," said Dr. Suphamai Bunnapradist, M.D., Professor of Medicine and Director of Kidney Transplant Research at the Ronald Reagan Medical Center and David Geffen School of Medicine at UCLA, California, USA. "This is important because once-daily dosing should be beneficial for kidney transplant patients who are on life-long complex therapy."
LCP-Tacro demonstrated non-inferiority to Prograf in preventing kidney transplant rejection, including in the early post-transplant period
The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection or BPAR, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro compared to Prograf.
The treatment failure rate for LCP-Tacro was 18.3% compared to 19.6% for Prograf, well within the 10% pre-specified non-inferiority margin.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Kudos To "The Independent" Newspaper For Debunking Nibiru "Blood Moon" Hoax
- USDA Microbiologist Warns Bacteria In Vaping Products May Be A Health Concern
- Your Microbiome Did Not Cause Your Weight Problem
- Control Cancer By Making The Tumor Cell Environment Hostile
- A Great Blitz Game
- Gödel,Frenkel, Kurzweil, and Hawkins on AI
- Beekeeping Fad And The Stress Of Traveling Is Harmful To Bees
- "Stacey, I already have. But sometimes I find new ways to explain these things which seem to help..."
- "Mr walker please would you be able to demonstrate how this cant be real or at least show hard evidence..."
- "germs, microbes, bacteria, etc.apparently cannot feed on pg, vg, or nicotine. The flavorings commonly..."
- "Oh, I wonder if you were lucky enough to see a rare sun mirage? Actually every time you see..."
- "I dont know much about this topic, however, I am certain of what I saw yesterday at sunset and..."
- Breast Cancer: Genomics May Show Where Chemo Might Not Be Needed
- Gallup Poll: Great Example of How to Bias a Social Science Study
- Another Kardashian Craze Debunked
- Fad Friday: Ditch The Body Wrap!
- Commonly Cited Stat of 10 Bacteria for Every 1 Human Cell Is Wrong
- Why The EpiPen And Other Generic Drugs Are So Expensive
- Activity tracker uses heart rate to personalize amount of exercise needed to prevent death
- Moderate physical activity linked with 50 percent reduction in cardiovascular death in over-65s
- 20 cent school intervention stops unhealthy weight gain in children
- Low socioeconomic status associated with higher risk of second heart attack or stroke
- Smartphone detects atrial fibrillation with existing hardware